Pinebridge Investments L.P. reduced its holdings in shares of Incyte Corporation (NASDAQ:INCY) by 1.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 73,754 shares of the biopharmaceutical company’s stock after selling 836 shares during the period. Pinebridge Investments L.P.’s holdings in Incyte were worth $8,610,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of INCY. Tower Research Capital LLC TRC increased its holdings in Incyte by 13.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 108 shares during the period. Seven Eight Capital LP purchased a new position in shares of Incyte in the 2nd quarter valued at $129,000. IFP Advisors Inc increased its holdings in shares of Incyte by 9.9% in the 2nd quarter. IFP Advisors Inc now owns 1,146 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 103 shares during the period. Sun Life Financial INC increased its holdings in shares of Incyte by 9,069.2% in the 2nd quarter. Sun Life Financial INC now owns 1,192 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 1,179 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its holdings in shares of Incyte by 130.4% in the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,325 shares of the biopharmaceutical company’s stock valued at $177,000 after acquiring an additional 750 shares during the period. 90.86% of the stock is owned by hedge funds and other institutional investors.

In related news, Director Bros. Advisors Lp Baker purchased 100,000 shares of the company’s stock in a transaction dated Friday, September 8th. The stock was acquired at an average cost of $132.00 per share, for a total transaction of $13,200,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Paul A. Friedman sold 28,507 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $105.24, for a total value of $3,000,076.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 106,638 shares of company stock valued at $12,339,027. 17.70% of the stock is owned by company insiders.

INCY has been the topic of a number of analyst reports. Argus reiterated a “buy” rating and issued a $150.00 price target on shares of Incyte in a report on Wednesday, September 13th. J P Morgan Chase & Co reissued a “buy” rating on shares of Incyte in a research report on Wednesday, October 25th. Goldman Sachs Group began coverage on Incyte in a research report on Friday, October 6th. They issued a “buy” rating and a $160.00 price objective for the company. Jefferies Group reissued a “buy” rating on shares of Incyte in a research report on Friday, October 6th. Finally, Oppenheimer reissued a “hold” rating and issued a $135.00 price objective on shares of Incyte in a research report on Thursday, August 31st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Incyte currently has an average rating of “Buy” and a consensus price target of $145.65.

Incyte Corporation (NASDAQ INCY) opened at $97.94 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.81 and a current ratio of 4.82. Incyte Corporation has a 52 week low of $94.78 and a 52 week high of $153.15.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.11. Incyte had a negative return on equity of 12.91% and a negative net margin of 10.90%. The firm had revenue of $381.50 million during the quarter, compared to analyst estimates of $360.34 million. During the same quarter in the previous year, the business earned $0.19 EPS. Incyte’s revenue for the quarter was up 41.6% compared to the same quarter last year. analysts anticipate that Incyte Corporation will post -1.33 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Incyte Corporation (INCY) Shares Sold by Pinebridge Investments L.P.” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/04/incyte-corporation-incy-shares-sold-by-pinebridge-investments-l-p.html.

About Incyte

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Stock Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related stocks with our FREE daily email newsletter.